Barclays Raises Price Target for Eli Lilly to $1,400 Amid Tirzepatide Momentum
Barclays analyst Emily Field raised the price target for Eli Lilly (LLY) from $1,350 to $1,400 following strong Q1 revenue growth and momentum around tirzepatide. The firm cited a 56% YoY increase in revenue to $19.8 billion and robust performance of Mounjaro and Zepbound as key drivers.
Topics: Eli Lilly GLP-1 Pharmaceuticals Tirzepatide